Campbell Newman Asset Management’s Corcept Therapeutics CORT Stock Holding History

Campbell Newman Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Buy	18,048 +797	+5%	+$48.1K	0.12%	71
2026 Q1	$695K	Buy	17,251 +320	+2%	+$12K	0.06%	95
2025 Q4	$589K	Sell	16,931 -18,599	-52%	-$1.46M	0.04%	104
2025 Q3	$2.95M	Buy	35,530 +170	+0.5%	+$12.3K	0.22%	54
2025 Q2	$2.6M	Buy	35,360 +2,375	+7%	+$172K	0.21%	57
2025 Q1	$3.77M	Sell	32,985 -16,142	-33%	-$982K	0.32%	40
2024 Q4	$2.48M	Sell	49,127 -247	-0.5%	-$12.9K	0.2%	52
2024 Q3	$2.29M	Sell	49,374 -809	-2%	-$28.7K	0.17%	57
2024 Q2	$1.63M	Sell	50,183 -85	-0.2%	-$2.33K	0.13%	70
2024 Q1	$1.27M	Buy	50,268 +1,181	+2%	+$27.9K	0.1%	85
2023 Q4	$1.59M	Buy	49,087 +211	+0.4%	+$5.79K	0.14%	69
2023 Q3	$1.33M	Sell	48,876 -861	-2%	-$24.9K	0.13%	75
2023 Q2	$1.11M	Buy	49,737 +1,092	+2%	+$25.1K	0.1%	83
2023 Q1	$1.05M	Buy	48,645 +459	+1%	+$10.1K	0.1%	84
2022 Q4	$979K	Buy	48,186 +1,528	+3%	+$38.3K	0.1%	83
2022 Q3	$1.2M	Buy	46,658 +1,116	+2%	+$29.9K	0.13%	72
2022 Q2	$1.08M	Buy	45,542 +1,974	+5%	+$43K	0.11%	72
2022 Q1	$981K	Buy	43,568 +846	+2%	+$18K	0.09%	90
2021 Q4	$846K	Buy	42,722 +1,126	+3%	+$22.8K	0.08%	95
2021 Q3	$819K	Buy	41,596 +2,177	+6%	+$45.6K	0.08%	97
2021 Q2	$867K	Buy	39,419 +2,012	+5%	+$44.8K	0.09%	94
2021 Q1	$890K	Buy	37,407 +1,770	+5%	+$47.3K	0.09%	95
2020 Q4	$932K	Buy	35,637 +2,682	+8%	+$56.5K	0.11%	85
2020 Q3	$574K	Buy	32,955 +611	+2%	+$9.74K	0.07%	98
2020 Q2	$544K	Buy	32,344 +304	+0.9%	+$4.27K	0.07%	95
2020 Q1	$381K	Sell	32,040 -1,540	-5%	-$19.1K	0.07%	99
2019 Q4	$406K	Sell	33,580 -53	-0.2%	-$738	0.05%	112
2019 Q3	$475K	Sell	33,633 -271	-0.8%	-$3.33K	0.07%	108
2019 Q2	$378K	Buy	33,904 +2,267	+7%	+$25.3K	0.06%	114
2019 Q1	$371K	Buy	31,637 +815	+3%	+$10.1K	0.06%	117
2018 Q4	$412K	Buy	30,822 +3,248	+12%	+$42.9K	0.07%	106
2018 Q3	$387K	Buy	+27,574	New	+$385K	0.06%	117

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell Newman Asset Management's CORT Position: Q2 2026 in Review

Campbell Newman Asset Management increased its Corcept Therapeutics (CORT) stake by 4.6% in Q2 2026, buying an estimated $48.1K and bringing the position to 18,048 shares worth $1.57M. The position accounts for 0.12% of the portfolio, ranked #71.

Campbell Newman Asset Management first reported a position in CORT in Q3 2018 and has held it in 32 quarters since. The position peaked at $3.77M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Campbell Newman Asset Management held 18,048 shares of Corcept Therapeutics worth $1.57M as of Q2 2026.
Campbell Newman Asset Management bought 797 Corcept Therapeutics shares in Q2 2026, an estimated $48.1K.
Corcept Therapeutics made up 0.12% of Campbell Newman Asset Management's portfolio in Q2 2026, its #71 holding.
Campbell Newman Asset Management first reported a position in Corcept Therapeutics in Q3 2018 and has held it in 32 quarters since.
Campbell Newman Asset Management's Corcept Therapeutics position peaked at $3.77M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Campbell Newman Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.